ExpreS2ion Biotech Holding AB Cash Flow-to-Debt Ratio
ExpreS2ion Biotech Holding AB cash flow-to-debt ratio. ExpreS2ion Biotech Holding AB (EXPRS2) has a Cash Flow-to-Debt Ratio of -1.06x as of March 2026, meaning its operating cash flow of Skr-25.49 Million could theoretically repay -1% of its total liabilities (Skr23.98 Million) in one year. See ExpreS2ion Biotech Holding AB leverage flexibility ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of ExpreS2ion Biotech Holding AB (2016–2025)
Cash flow-to-debt ratio of ExpreS2ion Biotech Holding AB from 2016 to 2025. Historical debt coverage capacity for ExpreS2ion Biotech Holding AB across 10 annual periods. Check ExpreS2ion Biotech Holding AB investment reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
ExpreS2ion Biotech Holding AB Cash Flow-to-Debt Ratio by Year (2016–2025)
ExpreS2ion Biotech Holding AB cash flow-to-debt ratio by year from 2016 to 2025. Year-by-year debt coverage analysis for ExpreS2ion Biotech Holding AB. For the full cash flow conversion analysis, see EXPRS2 operating cash flow.
| Year | CF-to-Debt Ratio | Operating CF (SEK) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -1.39x | Skr-40.90 Million | Skr29.42 Million | ▼ -64.4% |
| 2024 | -0.85x | Skr-33.93 Million | Skr40.11 Million | ▲ +88.8% |
| 2023 | -7.57x | Skr-100.89 Million | Skr13.33 Million | ▼ -158.6% |
| 2022 | -2.93x | Skr-99.61 Million | Skr34.04 Million | ▲ +25.6% |
| 2021 | -3.93x | Skr-45.65 Million | Skr11.61 Million | ▼ -425.9% |
| 2020 | -0.75x | Skr-18.18 Million | Skr24.31 Million | ▼ -16.6% |
| 2019 | -0.64x | Skr-12.69 Million | Skr19.79 Million | ▲ +37.0% |
| 2018 | -1.02x | Skr-12.88 Million | Skr12.65 Million | ▼ -24.1% |
| 2017 | -0.82x | Skr-8.61 Million | Skr10.50 Million | ▼ -37.1% |
| 2016 | -0.60x | Skr-7.02 Million | Skr11.73 Million | — |